Octreotide: Nursing Drug Guide, IV Bradycardia Risk & NCLEX Review

Octreotide is a synthetic somatostatin analogue. Verify the exact product, concentration, and route on every order—strengths are expressed in micrograms (mcg), not milligrams.

Common brand names include Sandostatin (octreotide acetate injection for subcutaneous or intravenous use) and multiple generic octreotide acetate injection products. Long-acting depot formulations (e.g., Sandostatin LAR, octreotide acetate for injectable suspension) are separate products with different dosing schedules; this guide focuses on immediate-release injection per Sandostatin Injection prescribing information.

Sandostatin Injection is indicated for acromegaly, metastatic carcinoid tumors with severe diarrhea and flushing, and VIP-secreting tumors with profuse watery diarrhea. Labeling notes that improvement in tumor size or growth rate was not shown in clinical trials for Sandostatin Injection.

↔On a small screen, swipe or scroll sideways to see the full table.

Off-label and protocol-driven uses (e.g., variceal hemorrhage, pancreatitis, carcinoid crisis) may occur in practice but are not listed as FDA-approved indications for Sandostatin Injection in the reviewed prescribing information. Follow institutional protocols and prescriber orders.

Octreotide mimics somatostatin and is a more potent inhibitor of growth hormone (GH), glucagon, and insulin than native somatostatin. It suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide. These actions reduce flushing and secretory diarrhea in carcinoid and VIPoma syndromes and lower GH/IGF-1 in acromegaly. Nurses should expect altered glucose balance, slowed gallbladder motility, and cardiac conduction effects—especially with intravenous administration.

Dosing is indication-specific and titrated to biochemical or symptom response. Sandostatin Injection may be given subcutaneously or intravenously. Institutional protocols and product formulations may vary—always verify mcg strength (50, 100, or 500 mcg/mL) and route before administration.

IV administration (labeling): May dilute in 50–200 mL and infuse over 15–30 minutes, or IV push over 3 minutes. In emergency situations (e.g., carcinoid crisis), rapid bolus may be used per prescriber and protocol. Continuous IV infusion safety is not established for approved indications—postmarketing complete AV block occurred mainly with higher-than-recommended doses and/or continuous infusion.

Renal/hepatic adjustment: In severe renal failure requiring dialysis or cirrhotic patients, half-life may be increased—maintenance dosage adjustment may be necessary per labeling.

Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber or pharmacist for missed scheduled doses.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Verify order: drug name, mcg dose, route (SC vs IV), concentration (50/100/500 mcg/mL), and infusion rate if IV
• Review cardiac history, baseline heart rate, and concomitant beta-blockers or other bradycardia-inducing drugs
• Check recent blood glucose and diabetes medications (insulin, oral agents); perform medication reconciliation
• Assess for gallbladder or biliary symptoms, abdominal pain, and signs of malabsorption (steatorrhea, weight loss)
• Inspect ampule for particulates/discoloration; confirm allergy to octreotide or excipients

Contraindications

• Hypersensitivity to octreotide or any component of the formulation

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Routes: Deep subcutaneous (intrafat) or intravenous per Sandostatin Injection labeling.

• Subcutaneous: Rotate injection sites systematically; use smallest volume that delivers the ordered mcg dose to reduce injection-site pain (reported in 7.7% of patients). Follow subcutaneous injection technique.
• IV: Dilute 50–200 mL and infuse 15–30 minutes, or IV push over 3 minutes per labeling. Use IV infusion pump setup and independent double-check for mcg/hour or bolus orders. Consider cardiac monitoring during IV therapy per labeling.
• Do not administer in total parenteral nutrition (TPN) solutions—incompatible (glycosyl octreotide conjugate may reduce efficacy)
• Not specified in the reviewed prescribing information whether standard IV line flushing requirements differ from institutional policy after octreotide administration

• Reduced flushing and secretory diarrhea in carcinoid or VIPoma syndromes
• Decreasing GH and IGF-1 toward treatment goals in acromegaly (GH <5 ng/mL or normal IGF-1 per labeling)
• Stable heart rate and blood glucose without symptomatic highs or lows
• Absence of new biliary colic, steatorrhea, or progressive abdominal distension suggesting gallbladder or malabsorption complications

Octreotide’s highest-stakes bedside risks are cardiac conduction block (especially IV), dangerous glucose shifts, and acute biliary or pancreatic complications.

• Severe bradycardia, hypotension, syncope, or suspected high-degree AV block during or after IV dose—hold drug, initiate cardiac monitoring, escalate urgently
• Symptoms of hyperglycemia or hypoglycemia—check capillary glucose immediately and notify prescriber
• Right upper quadrant abdominal pain, fever, jaundice, or worsening steatorrhea suggesting cholecystitis, cholangitis, or pancreatitis—hold octreotide if complications of cholelithiasis suspected per labeling
• Anaphylaxis or anaphylactoid reaction (including shock) reported postmarketing—stop permanently and treat per protocol
• Progressive abdominal distension with severe epigastric pain and guarding (rare intestinal obstruction-like presentation per labeling)

↔On a small screen, swipe or scroll sideways to see the full table.

Limited accidental overdoses in adults have been reported with continuous infusion (2400–6000 mcg/day) or high subcutaneous doses (e.g., 1500 mcg TID). Reported events included arrhythmia, complete AV block, hypotension, cardiac arrest, brain hypoxia, pancreatitis, hepatitis steatosis, hepatomegaly, lactic acidosis, flushing, diarrhea, lethargy, weakness, and weight loss.

Antidote

No specific antidote is listed in the reviewed prescribing information. Management is symptomatic and supportive.

• mcg vs mg—octreotide doses are micrograms; decimal errors are high-risk
• Octreotide immediate-release injection vs long-acting depot (LAR)—different products, schedules, and monitoring; verify formulation on MAR
• Octreotide vs other somatostatin analogues (e.g., lanreotide)—do not substitute without prescriber and pharmacy approval
• IV push vs continuous infusion—continuous infusion for approved indications is not established as safe; complete AV block reported with non-recommended regimens
• Concentration mix-ups—50, 100, and 500 mcg/mL ampules; independent double-check before draw-up

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Heart rate, blood pressure, and rhythm—especially during IV administration; obtain ECG per prescriber when conduction disease or symptomatic bradycardia
• Blood glucose per protocol and whenever symptoms occur; use blood glucose monitoring
• Thyroid function (TSH, total and/or free T4) at baseline and periodically during chronic therapy
• Gallbladder/biliary symptoms; consider imaging per prescriber for long-term therapy
• GH/IGF-1, urinary 5-HIAA, serotonin, substance P, or VIP levels when ordered for acromegaly or neuroendocrine tumors
• Signs of steatorrhea, weight loss, or fat malabsorption—evaluate pancreatic exocrine insufficiency if new or worsening per labeling

Document

• mcg dose, concentration, route, site (SC), infusion rate/duration (IV), and patient response
• Glucose values and any antidiabetic adjustments communicated to the team
• Cardiac monitoring in place for IV doses and any arrhythmia or bradycardia events
• Patient teaching on glucose self-checks, biliary pain, and when to seek urgent care

• This medicine can raise or lower blood sugar—know your glucose targets and report dizziness, confusion, excessive thirst, or frequent urination
• Report slow heartbeat, dizziness, fainting, or palpitations—especially after IV doses
• Report severe stomach pain, fever, yellowing skin, or fatty stools that may suggest gallbladder or pancreas problems
• Rotate injection sites if using subcutaneous octreotide at home; report persistent injection-site pain
• Do not stop or change dose without prescriber guidance; carry glucose source if prone to hypoglycemia
• For overdose or severe reactions, seek emergency care and contact local poison control / toxicology per your facility’s instructions

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for octreotide using a tabbed case (MAR, labs, vitals/history, nursing notes), then priority action, select-all-that-apply cue recognition, glucose trend interpretation, documentation cloze, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes around IV bradycardia and glucose shifts.